<DOC>
	<DOCNO>NCT01215643</DOCNO>
	<brief_summary>The study investigate whether alisporivir ( ALV ; DEB025 ) alone combination either ribavirin ( RBV ) peginterferon alfa-2a ( PEG ) efficient compare standard care ( PEG+RBV ) treatment-naïve participant hepatitis C virus ( HCV ) genotype 2 3 . In addition , triple therapy DEB025 plus standard care apply participant achieve rapid viral response ( RVR ) different arm .</brief_summary>
	<brief_title>Efficacy Safety Alisporivir Alone Combined With RBV PEG Chronic Hepatitis C Genotype 2 3 Treatment-naïve Participants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion criterion : Chronic hepatitis C viral infection Plasma HCV RNA level lower limit ≥ 10,000 IU/ml assess quantitative polymerase chain reaction ( qPCR ) equivalent screening ( upper limit ) HCV genotype 2 3 No previous treatment hepatitis C infection Exclusion criterion : Evidence cirrhosis time screen Evidence hepatocellular carcinoma time screen Any cause relevant liver disease HCV Alanine aminotransferase ( ALT ) ≥ 10 time upper limit normal ( ULN ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Chronic hepatitis C genotype 2</keyword>
	<keyword>Chronic hepatitis C genotype 3</keyword>
	<keyword>Cyclophilin inhibitor</keyword>
</DOC>